Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$53.94
-2.2%		$57.42
$11.40
▼
$72.36
$1.60B0.71702,592 shs336,162 shs
Novavax, Inc. stock logo
NVAX
Novavax
$9.42
+1.3%		$8.63
$6.20
▼
$11.97
$1.55B2.454.75 million shs6.11 million shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$4.59
-1.7%		$5.07
$0.98
▼
$6.83
$366.28M0.97427,576 shs520,337 shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$22.03
-6.4%		$28.56
$11.82
▼
$40.65
$1.31B0.73916,127 shs1.55 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-0.97%-4.00%-4.68%-1.62%+142.14%
Novavax, Inc. stock logo
NVAX
Novavax
-5.58%-10.06%+16.98%+4.73%+16.83%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-8.25%-11.05%-12.22%+4.01%+292.44%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
+6.95%-5.31%-6.51%-12.78%+97.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$53.94
-2.2%		$57.42
$11.40
▼
$72.36
$1.60B0.71702,592 shs336,162 shs
Novavax, Inc. stock logo
NVAX
Novavax
$9.42
+1.3%		$8.63
$6.20
▼
$11.97
$1.55B2.454.75 million shs6.11 million shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$4.59
-1.7%		$5.07
$0.98
▼
$6.83
$366.28M0.97427,576 shs520,337 shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$22.03
-6.4%		$28.56
$11.82
▼
$40.65
$1.31B0.73916,127 shs1.55 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-0.97%-4.00%-4.68%-1.62%+142.14%
Novavax, Inc. stock logo
NVAX
Novavax
-5.58%-10.06%+16.98%+4.73%+16.83%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-8.25%-11.05%-12.22%+4.01%+292.44%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
+6.95%-5.31%-6.51%-12.78%+97.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.67
Moderate Buy$79.8548.03% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.33
Hold$14.0048.62% Upside
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
2.40
Hold$7.6767.03% Upside
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2.77
Moderate Buy$47.88117.32% Upside

Current Analyst Ratings Breakdown

Latest PRLD, ANAB, NVAX, and TYRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/10/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$53.00
9/10/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$45.00 ➝ $30.00
9/8/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$56.00
9/4/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
8/31/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$78.00
8/25/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$75.00 ➝ $70.00
8/25/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold$70.00
8/24/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$95.00
8/7/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$232.39M6.87N/AN/A$1.34 per share40.25
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.38$3.35 per share2.81($0.79) per share-11.92
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$12.14M30.17N/AN/A$1.09 per share4.21
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/A$4.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M-$1.08N/A18.16N/A-11.53%N/A-7.75%11/10/2026 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$1.52N/AN/AN/A-59.87%-14.82%-13.35%11/5/2026 (Estimated)
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$99.50M-$0.73N/AN/AN/AN/A-75.35%-44.39%11/11/2026 (Estimated)
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$119.95M-$2.40N/AN/AN/AN/A-46.39%-43.07%11/4/2026 (Estimated)

Latest PRLD, ANAB, NVAX, and TYRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.1967-$0.14+$0.0567-$0.14$5.70 million$5.70 million
8/6/2026Q2 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3798-$0.32+$0.0598-$0.32$52.51 million$56.70 million
8/4/2026Q2 2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.6499-$0.69-$0.0401-$0.69N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.33
2.30
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
4.07
4.07
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/A
14.90
14.91

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
79.72%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
84.14%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
31.50%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
49.20%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10029.61 million20.28 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990164.95 million162.31 millionOptionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12079.80 million40.54 millionOptionable
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2059.68 million52.22 millionOptionable

Recent News About These Companies

Tyra Biosciences (NASDAQ:TYRA) Director Buys $20,003.76 in Stock
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-tyra-biosciences-nasdaq-tyra-director-buys-2000376-in-stock-2026-09-11/
Tyra Biosciences (NASDAQ:TYRA) Shares Down 5.6% After Analyst Downgrade
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-tyra-biosciences-nasdaq-tyra-shares-down-56-after-analyst-downgrade-2026-09-11/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
September 10 at 7:20 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-tyra-biosciences-inc---tyra-302875825.html
Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib
September 10 at 2:06 PM  |  thepharmaletter.comT
Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 5.6% - Still a Buy?
September 10 at 12:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-tyra-biosciences-nasdaq-tyra-stock-price-up-56-still-a-buy-2026-09-10/
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
September 10 at 10:47 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4945056-tyra-biosciences-inc-tyra-discusses-initial-surf302-results-on-oral-dabogratinib-for
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC - Slideshow
September 10 at 10:07 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4945058-tyra-biosciences-inc-tyra-discusses-initial-surf302-results-on-oral-dabogratinib-for
Wedbush Reaffirms Outperform Rating for Tyra Biosciences (NASDAQ:TYRA)
September 10 at 9:17 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wedbush-reaffirms-outperform-rating-for-tyra-biosciences-nasdaq-tyra-2026-09-10/
Tyra announces initial data from Phase II SURF302 trial of dabogratinib
September 10 at 8:54 AM  |  yahoo.comhttps://www.yahoo.com/news/science/articles/tyra-announces-initial-data-phase-091527581.html
Tyra shares slip as bladder cancer responses fall short of investor expectations
September 10 at 8:54 AM  |  biospace.comB
Tyra Biosciences (NASDAQ:TYRA) Price Target Cut to $30.00 by Analysts at HC Wainwright
September 10 at 8:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-tyra-biosciences-nasdaq-tyra-price-target-cut-to-3000-by-analysts-at-hc-wainwright-2026-09-10/
Balversa reversa? Tyra’s bladder cancer drug hits in phase II
September 9 at 10:52 PM  |  bioworld.comB
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
September 9 at 5:51 PM  |  msn.comhttps://www.msn.com/en-us/news/other/tyra-biosciences-shares-plunge-30-after-phase-2-dabogratinib-data/ar-AA2bT0vX
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines
September 9 at 5:51 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4944515-tyra-biosciences-tanks-ir-nmibc-data-disappoints-firmly-on-sidelines
Tyra disappoints investors with bladder cancer data
September 9 at 5:51 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tyra-disappoints-investors-bladder-cancer-154600125.html
Why Is Tyra Biosciences Stock Sinking Wednesday?
September 9 at 1:00 PM  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/09/61693811/why-is-tyra-biosciences-stock-sinking-wednesday
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
September 9 at 12:50 PM  |  fiercebiotech.comF
Tyra Biosciences Stock Plunges 22% Despite Positive Bladder Cancer Data
September 9 at 12:50 PM  |  rttnews.comhttps://www.rttnews.com/3689657/tyra-biosciences-stock-plunges-22-despite-positive-bladder-cancer-data.aspx
Tyra Biosciences (TYRA) Stock Drops 22% After Bladder Cancer Drug Data Misses the Bar
September 9 at 12:50 PM  |  coincentral.comC
Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial
September 9 at 12:50 PM  |  marketwatch.comhttps://www.marketwatch.com/story/tyra-biosciences-shares-sink-after-bladder-cancer-treatment-causes-adverse-events-in-some-patients-during-clinical-trial-82e13966
Tyra drops after mid-stage trial data for lead asset in bladder cancer
September 9 at 12:50 PM  |  msn.comhttps://www.msn.com/en-us/money/general/tyra-drops-after-mid-stage-trial-data-for-lead-asset-in-bladder-cancer/ar-AA2bSfYL

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$53.94 -1.22 (-2.21%)
Closing price 04:00 PM Eastern
Extended Trading
$53.66 -0.28 (-0.52%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$9.42 +0.12 (+1.29%)
Closing price 04:00 PM Eastern
Extended Trading
$9.51 +0.09 (+0.96%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$4.59 -0.08 (-1.71%)
Closing price 04:00 PM Eastern
Extended Trading
$4.55 -0.04 (-0.85%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Tyra Biosciences stock logo

Tyra Biosciences NASDAQ:TYRA

$22.03 -1.51 (-6.41%)
Closing price 04:00 PM Eastern
Extended Trading
$22.23 +0.20 (+0.89%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas